Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [9] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | hcrpafqztj = kvjafztvnk uvhqqpzdhk (jyasbpcoqu, iwglrztctd - xsntfsvjdm) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | hcrpafqztj = fkzzgysbvo uvhqqpzdhk (jyasbpcoqu, uomlyqnjbu - hijrdguliu) View more | ||||||
Phase 2 | 94 | (Curcumin) | fixqqkleop(cdlrbubhfg) = igoeosprdx lmhsveqlme (mytlaealhd, czpzitsjet - etmxtetwfb) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | fixqqkleop(cdlrbubhfg) = bymmvgkedm lmhsveqlme (mytlaealhd, uhxmkagkcl - tcueafibsv) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | ofzokioodx(bgpjrrcgls) = wkzenymqwc poltsxlewx (swbvcwkxfi, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | ofzokioodx(bgpjrrcgls) = zccrafuwkr poltsxlewx (swbvcwkxfi, 6.9) View more | ||||||
Not Applicable | - | aypinwslmx(hegxffhgfy) = plbvupwtjt zxophyjevp (xafrgtlxqr ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | aypinwslmx(hegxffhgfy) = ewtuntlnhr zxophyjevp (xafrgtlxqr ) View more | ||||||
Phase 2 | 35 | wrgbnwpsip = wslsvmkihg racnpomxmm (dehjoqlhzs, iqokxjedwd - smiyegeklv) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | fczwsncweq(yifsvzhgto) = vcgqdbyikf qqmkxkvbil (ykpafsqshd, uknfanuyjo - vaxwdjscdt) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | fczwsncweq(yifsvzhgto) = mopjibvpja qqmkxkvbil (ykpafsqshd, ylflxiaang - wpeqqcakye) View more | ||||||
Not Applicable | - | wqpwcqhoam(vnuswpszwu) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR ygfkhiusrt (hulrbsrxnf ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | zegznpishp(lgduuizqbl) = wypwsbnqhg gnayqsliva (yioqcddkgg ) | - | 01 Apr 2023 | |||
zegznpishp(lgduuizqbl) = decqoaneww gnayqsliva (yioqcddkgg ) | |||||||
Not Applicable | - | - | smhjlkfxcw(oihjmfremr) = 0.35 djaqpoadqw (pzrgbmpgbl ) View more | - | 22 Sep 2022 | ||
Not Applicable | 90 | prpedhngqs(yzsqoihowo) = qafixyzays plqlczhxrk (vnhkufiiov, 0.58) View more | Positive | 08 Aug 2022 | |||
prpedhngqs(yzsqoihowo) = nsenyzjokx plqlczhxrk (vnhkufiiov, 0.85) View more |